First, telaprevir and boceprevir are likely to be approved next year as add-ons to the current treatment regimen. The second
wave, in three to five years, will bring second-generation protease blockers, a crop of polymerase inhibitors, and new classes of compounds such as Bristol-Myers Squibb’s NS5A inhibitor and Debiopharm’s cyclophilin inhibitor.